Annexin A2 expression in prostate cancer cells by Gates, Charles R. et al.
ABSTRACT RESULTS
ANNEXIN A2 EXPRESSION IN PROSTATE CANCER CELLS.
Charles R. Gates1,2, Amit Kumar Tripathi1, Jamboor K. Vishwanatha1, Pankaj Chaudhary1
1Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX. 
2Department of Biology, Langston University, Langston, OK.
REFERENCES
 Mundy GR. (2002) Metastasis to bone: causes, consequences and therapeutic
opportunities. Nat Rev Cancer. 2 (8), 584‐593.
 Msaouel P, Pissimissis N, Halapas A, Koutsilieris M. (2008) Mechanisms of bone
metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol
Metab. 22 (2), 341‐355.
 Hajjar KA, Krishnan S (1999) Annexin II: A mediator of the plasmin/ plasminogen
activator system. Trends Cardiovasc Med. 9(5): 128-138.
 Bharadwaj A, Bydoun M, Holloway R, Waisman D (2013) Annexin A2
heterotetramer: structure and function. Int J Mol Sci 14: 6259–6305.
 Tan SH, Young D, Chen Y, Kuo HC, Srinivasan A, Dobi A, Petrovics G, Cullen J,
Mcleod DG, Rosner IL, Srivastava S, Sesterhenn IA. (2021) Prognostic features of
Annexin A2 expression in prostate cancer. Pathology. 53(2):205-213.
 Jung Y, Wang J, Song J, Shiozawa Y, Wang J, Havens A, Wang Z, Sun YX,
Emerson SG, Krebsbach PH, Taichman RS. (2007) Annexin II expressed by
osteoblasts and endothelial cells regulates stem cell adhesion, homing, and
engraftment following transplantation. Blood. 110(1):82-90.
 Jung Y, Wang J, Lee E, McGee S, Berry JE, Yumoto K, Dai J, Keller ET, Shiozawa
Y, Taichman RS. (2015) Annexin 2-CXCL12 interactions regulate metastatic cell
targeting and growth in the bone marrow. Mol Cancer Res. 13(1):197-207.
ACKNOWLEDGEMENTS
Research reported in this poster was supported by the “National Heart, Lung, and
Blood Institute” of the “National Institutes of Health” under the Award Number
R25HL007786. The content is solely the responsibility of the authors and does not
necessarily the official views of the National Institutes of Health.
Background: Metastasis is a major cause of morbidity in prostate cancer
patients, the primary mortality in this disease is metastasis to the bone tissue.
Despite substantial efforts to understand prostate cancer metastasis, the
mechanisms that are involved in preparing the metastatic niche for colonizing the
prostate cancer cells are still not known. Therefore, there is an urgent need to
identify essential regulators of bone metastasis in prostate cancer for therapeutic
targets.
Purpose: Annexin A2 (AnxA2), a calcium-dependent phospholipid binding
protein, is overexpressed in the poorly differentiated high-grade adenocarcinomas
of prostate cancer. AnxA2 exists as a monomer in the cytosol and as a
heterotetrameric complex with S100A10 [(AnxA2)2-(S100A10)2] at the cell
surface. Phosphorylation of AnxA2 at tyrosine 23 (pAnxA2-Y23) is an important
event for the localization of AnxA2 to the cell surface. At the cell surface, AnxA2
heterotetramer complex provides binding site for tissue plasminogen activator
(tPA) and converts plasminogen into plasmin, which plays an important role in
invasion and metastasis of cancer. The cell surface AnxA2 also plays an
important role in hematopoietic stem cell localization to the marrow niche and
regulates osteogenic differentiation. However, the cell surface expression of
AnxA2 in prostate cancer is unknown. Therefore, in the present study, we have
demonstrated the cell surface expression of AnxA2 in prostate cancer cells to
delineate the mechanism of bone metastasis.
Methods: Prostate cancer cell lines, PC3 and DU145 were grown in RPMI-1640
medium containing 10% fetal bovine serum, in a humidified incubator at 37ºC with
5% CO2. The RWPE1, and PWR-1E cells were cultured in keratinocyte growth
medium supplemented with 5 ng/ml human recombinant epidermal growth factor
and 0.05 mg/ml bovine pituitary extract (Invitrogen, Carlsbad, CA) and maintained
in an incubator under the conditions described above. Immunoblotting was used
to detect the expression of pAnxA2-Y23 and AnxA2 proteins in cells.
Results: Our results demonstrated that the expression of pAnxA2-Y23 is very
high in prostate cancer cells (PC3 and DU145 cells) compared to normal prostate
epithelial (PWR1E, and RWPE1 cells). However, the expression of total AnxA2 in
both prostate normal and cancer cell lines is comparable. In addition, our
membrane wash experiment showed that a large amount of AnxA2 is present at
the cell surface of the PC3 and DU145 cell lines. In normal prostate epithelial
cells, even though the expression of total AnxA2 is comparable to PC3 and
DU145 prostate cancer cells, membrane localization of AnxA2 is very low.
Conclusion: Our results clearly suggest that the cell surface expression of AnxA2
is high in prostate cancer cells due to increased phosphorylation of AnxA2 at
tyrosine 23.
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Expression of pAnxA2-Y23 and AnxA2 in human prostate
normal and cancer cell lines:
Cell surface expression of AnxA2 in human prostate normal
and cancer cell lines by membrane wash experiment:
The expression of pAnxA2-Y23 and
total AnxA2 were analyzed by
immunoblotting in prostate normal
and cancer cell lines. Our results
demonstrated that expression of
pAnxA2-Y23 is high in prostate
cancer cell lines (PC3 and DU145
cells) compared to prostate normal
(PWR1E, and RWPE1) cell lines.
However, the expression of total
AnxA2 in these cell lines is
comparable. The expression of β-
actin was used as loading control.
Increased phosphorylation of AnxA2 at
Y23 is associated with increased
translocation of AnxA2 to the outer
surface of the cells. Therefore, we
compared the cell-surface localization of
AnxA2 in prostate normal and cancer cell
lines. AnxA2 heterotetramers are Ca++-
dependent phospholipid-binding proteins,
and are stripped from the cell surface by
Versene (0.53 mM EDTA in PBS).
Therefore, cells were incubated with
Versene for 5 min and then supernatant
was collected by centrifugation for
immunoblotting. Our results
demonstrated that in PC3 and DU145
cell lines, a large amount of AnxA2 is
present in the membrane wash fraction
compared to normal prostate epithelial
(RWPE1 and PWR1E cells) cell lines.
Coomassie blue staining of Versene
eluates was used as a loading control.
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IMPORTANT FINDINGS
 AnxA2 phosphorylation at tyrosine 23 is significantly high in
prostate cancer cells compared to normal prostate epithelial
cells.
 The cell surface expression of AnxA2 is significantly high in
prostate cancer compared to normal prostate epithelial cells.
